Literature DB >> 15607958

Crosslinks and crosstalk: human cancer syndromes and DNA repair defects.

Mary A Risinger1, Joanna Groden.   

Abstract

A subset of human cancer syndromes result from inherited defects in genes responsible for DNA repair. During the past few years, discoveries concerning the intersection of certain DNA repair processes have increased our understanding of how the disruption of specific DNA repair mechanisms leads to genomic instability and tumorigenesis. This review focuses on the human genes MUTYH, BRCA2/FANCD1, and BLM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15607958     DOI: 10.1016/j.ccr.2004.12.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  21 in total

Review 1.  [Hereditary photodermatoses].

Authors:  P Poblete-Gutiérrez; W H C Burgdorf; C Has; M Berneburg; J Frank
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

2.  Genetic Manipulation of Homologous Recombination In Vivo Attenuates Intestinal Tumorigenesis.

Authors:  Michael A McIlhatton; Kevin Murnan; Daniel Carson; Gregory P Boivin; Carlo M Croce; Joanna Groden
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-23

Review 3.  Modifiers of CAG/CTG Repeat Instability: Insights from Mammalian Models.

Authors:  Vanessa C Wheeler; Vincent Dion
Journal:  J Huntingtons Dis       Date:  2021

4.  FANCJ/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses.

Authors:  Fan Zhang; Qiang Fan; Keqin Ren; Arleen D Auerbach; Paul R Andreassen
Journal:  Chromosoma       Date:  2010-07-31       Impact factor: 4.316

5.  The association of polymorphisms in DNA base excision repair genes XRCC1, OGG1 and MUTYH with the risk of childhood acute lymphoblastic leukemia.

Authors:  M Stanczyk; T Sliwinski; M Cuchra; M Zubowska; A Bielecka-Kowalska; M Kowalski; J Szemraj; W Mlynarski; I Majsterek
Journal:  Mol Biol Rep       Date:  2010-04-04       Impact factor: 2.316

Review 6.  Targeting the LKB1 tumor suppressor.

Authors:  Rui-Xun Zhao; Zhi-Xiang Xu
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 7.  HMGNs, DNA repair and cancer.

Authors:  Gabi Gerlitz
Journal:  Biochim Biophys Acta       Date:  2009-12-08

8.  Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Authors:  Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

9.  A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.

Authors:  Joseph Vijai; Sabine Topka; Danylo Villano; Vignesh Ravichandran; Kara N Maxwell; Ann Maria; Tinu Thomas; Pragna Gaddam; Anne Lincoln; Sarah Kazzaz; Brandon Wenz; Shai Carmi; Kasmintan A Schrader; Steven N Hart; Steve M Lipkin; Susan L Neuhausen; Michael F Walsh; Liying Zhang; Flavio Lejbkowicz; Hedy Rennert; Zsofia K Stadler; Mark Robson; Jeffrey N Weitzel; Susan Domchek; Mark J Daly; Fergus J Couch; Katherine L Nathanson; Larry Norton; Gad Rennert; Kenneth Offit
Journal:  Cancer Discov       Date:  2016-09-21       Impact factor: 39.397

Review 10.  Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.

Authors:  Paul R Andreassen; Keqin Ren
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.